Farwell Wildon
Known title: Chief Medical OfficerCIK: 0001847941
Associated companies
Transaction History
| DYN | ▼ Sell | Open Market | 2,060 | $93K | 8/19/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 261 | $12K | 8/19/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,628 | $51K | 6/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,008 | $32K | 6/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,956 | $55K | 5/16/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 425 | $12K | 5/16/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,030 | $26K | 3/12/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,585 | $41K | 3/11/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 8,364 | $216K | 3/7/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 1,557 | $41K | 3/7/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 407 | $10K | 2/28/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 5,493 | $138K | 2/12/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 100 | $3K | 1/26/2024 | View on chart |
| DYN | ▼ Sell | Open Market | 978 | $10K | 12/12/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,688 | $18K | 12/11/2023 | View on chart |
| DYN | ▲ Buy | Grant | 82,512 | $0 | 11/15/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,707 | $18K | 9/12/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 1,698 | $21K | 6/13/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 7,441 | $99K | 3/14/2023 | View on chart |
| DYN | ▼ Sell | Open Market | 628 | $7K | 12/12/2022 | View on chart |
| DYN | ▲ Buy | Grant | 36,000 | $0 | 12/9/2022 | View on chart |
| DYN | ▼ Sell | Other | 658 | $9K | 9/15/2022 | View on chart |
| DYN | ▼ Sell | Other | 668 | $3K | 6/14/2022 | View on chart |
| DYN | ▼ Sell | Open Market | 640 | $6K | 3/11/2022 | View on chart |
| DYN | ▼ Sell | Open Market | 5,617 | $48K | 3/2/2022 | View on chart |
| DYN | ▲ Buy | Grant | 22,307 | $0 | 12/10/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Dyne Therapeutics highlighted in recent healthcare stock coverage
Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.
Dyne Therapeutics highlighted in recent healthcare stock coverage. Dyne Therapeutics appeared in a Benzinga pre‑market roundup of 12 health‑care stocks. Yahoo highlighted the company in a piece about why it is back in the spotlight, and Raymond James analysts listed it among four health‑care stocks they back. The coverage brings renewed attention to DYN as it trades near its recent support level.